BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 8, 2011
View Archived Issues
Promising data described from several trials of natalizumab in RRMS
Read More
Incyte and Pfizer disclose favorable preclinical data on chemokine CCR2 receptor antagonist
Read More
Phase III results show immunogenicity of quadrivalent flu vaccine in children
Read More
Actilyse approved in 15 European countries to treat acute ischemic stroke
Read More
Nitazoxanide evaluated in viral respiratory infections
Read More
Researchers at Novartis disclose new kinesin-like protein KIF11 inhibitors
Read More
Novel candidate therapeutics prepared for ophthalmic diseases
Read More
Sanofi presents novel protease-activated PAR1 receptor antagonists
Read More
New MAP kinase p38 inhibitors designed by RespiVert
Read More
NanoViricides raises funds to advance new influenza candidate
Read More
Synageva BioPharma and Trimeris complete merger
Read More
Acadia Pharmaceuticals clear to test AM-831 in clinic
Read More
Novel HIV reverse transcriptase inhibitor prodrugs disclosed
Read More
Functional Genetics completes first-in-human FGI-101-1A6 trial
Read More
FDA recognizes Velcade extends survival of patients with multiple myeloma
Read More
NPS Pharmaceuticals reports topline results from phase III REPLACE study
Read More
Evolva clear to begin phase IIa development of EV-077 in diabetic complications
Read More
Daiichi Sankyo gains Brazilian rights to drug for overactive bladder
Read More
First RENAISSANCE phase III trial does not meet primary endpoint
Read More
Pilot study evaluates apremilast in ankylosing spondylitis
Read More
Novo Nordisk reports results from Japanese phase IIIa trial of DegludecPlus
Read More
FDA approves U.S. market return for Octagam
Read More
Artisan Pharma becomes wholly owned subsidiary of Asahi Kasei Pharma
Read More
Amgen to pay ImmunoGen milestone for use of TAP technology
Read More
Recordati's Normosang approved in Russia
Read More